![Raul Trillo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Raul Trillo
President chez
Vyluma Inc
Health Technology
Profil
Raul A. Trillo is currently working as the President & Chief Commercial Officer at Vyluma, Inc.
Postes actifs de Raul Trillo
| Sociétés | Poste | Début |
|---|---|---|
Vyluma Inc
 Vyluma Inc Pharmaceuticals: MajorHealth Technology Vyluma, Inc. is a biopharmaceutical company with an extensive portfolio of ophthalmic products focusing on refractive errors. The company is based in Bridgewater, NJ. The company develops novel therapies, including NVK-002, a preservative-free, pharmaceutically-produced atropine eyedrop intended to slow the progression of myopia in children. NVK-002 is currently in late phase III clinical development and has completed enrollment in the CHAMP (Childhood Atropine for Myopia Progression) clinical trial. Vyluma also has a pipeline of other pharmaceutical assets in various stages of development addressing unmet treatment needs for patients with refractive errors or eye pain. The company was founded by Navneet Puri. Navneet Puri has been the CEO since incorporation. | President | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Vyluma Inc
Vyluma Inc Pharmaceuticals: MajorHealth Technology Vyluma, Inc. is a biopharmaceutical company with an extensive portfolio of ophthalmic products focusing on refractive errors. The company is based in Bridgewater, NJ. The company develops novel therapies, including NVK-002, a preservative-free, pharmaceutically-produced atropine eyedrop intended to slow the progression of myopia in children. NVK-002 is currently in late phase III clinical development and has completed enrollment in the CHAMP (Childhood Atropine for Myopia Progression) clinical trial. Vyluma also has a pipeline of other pharmaceutical assets in various stages of development addressing unmet treatment needs for patients with refractive errors or eye pain. The company was founded by Navneet Puri. Navneet Puri has been the CEO since incorporation. | Health Technology |
